Sign In
Buy REPL
$9.98
+1.11 (+12.51%)
At Close: Jun 03, 2026
Replimune to Present at the William Blair Biotech Focus Conference 2021
08:00am, Wednesday, 07'th Jul 2021
WOBURN, Mass., July 07, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic® platform, today a
Buy The Replimune Dip Caused By Unrealistic Expectations
07:01pm, Friday, 04'th Jun 2021
The stock fell 12% on information suggesting RP1's weakness as monotherapy, which was doubtful, to begin with. However, the data solidified RP1's chances on its registrational trials and pointed towar
High rate of complete responses in RP1 skin cancer cohorts underscore the potential for profound patient benefit and supports the ongoing registration directed development programs
Replimune Reports Fiscal Fourth Quarter and Year-Ended 2021 Financial Results and Provides Corporate Update
08:00am, Thursday, 20'th May 2021
Added complete response as an independent primary endpoint in registration-directed CERPASS study in CSCC and held Type B meeting with FDA to discuss the IGNYTE study in anti-PD1 failed melanoma
Replimune: Oncolytic Immunotherapy Pioneer Gaining Momentum In The Clinic
01:29pm, Friday, 30'th Apr 2021
Shares have risen by 130% since my December 2019 recommendation but have lost a quarter of their value over the past three months. Lead indications for RP1 appear substantially derisked, while initial
Replimune to Host Virtual Investor Event on June 3, 2021
08:00am, Wednesday, 28'th Apr 2021
Event to begin at 8:00 AM ET Event to begin at 8:00 AM ET
Analysts See Plenty of Upside for Replimune
03:19pm, Thursday, 22'nd Apr 2021
Boston-area biotech Replimune Group Inc. (NASDAQ:REPL) just boosted its executive lineup with a heavy hitter, and the market seems to like the addition.
Data confirms potent anti-tumor activity & activation of robust systemic immune responses by RP1 and RP2
Replimune to Present at the American Association for Cancer Research Annual Meeting 2021
04:01pm, Thursday, 11'th Mar 2021
WOBURN, Mass., March 11, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today
Replimune to Present at Three Upcoming Investor Conferences
08:00am, Thursday, 04'th Mar 2021
WOBURN, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today
Replimune Reports Third Fiscal Quarter Financial Results and Provides Corporate Update
08:00am, Thursday, 04'th Feb 2021
RP1: Initial data in new indications expected in 2021 in anti-PD1 failed NSCLC, anti-PD1 failed CSCC and CSCC solid organ transplant recipient patients; further updates expected to be provided across
Replimune: Interesting Developer Of Oncolytic Immunotherapies
03:03am, Sunday, 06'th Dec 2020
Replimune is developing a handful of oncolytic immunotherapies therapies targeting cancers. The company has nearly half a billion dollars in cash.
2 Biotech Stocks That Could Have Tripled Your Money This Year
08:39am, Sunday, 15'th Nov 2020
One has a better chance to keep climbing than the other does.
Replimune Reports Fiscal Second Quarter Financial Results and Provides Corporate Update
08:00am, Thursday, 05'th Nov 2020
RP1 : Updated deep and durable response data with Opdivo ® in CSCC and anti- PD1 failed melanoma continue to support ongoing registration-directed development
2 Top Biotech Stocks From the IPO Class of 2018 to Buy Now
07:24am, Wednesday, 04'th Nov 2020
Compelling clinical trial results so far make these biotech stocks worth more attention than they've received so far.
